EuroInf 2 : Subthalamic stimulation, apomorphine, and levodopa infusion in Parkinson's disease
(2019) In Movement Disorders- Abstract
Objective: Real-life observational report of clinical efficacy of bilateral subthalamic stimulation (STN-DBS), apomorphine (APO), and intrajejunal levodopa infusion (IJLI) on quality of life, motor, and nonmotor symptoms (NMS) in Parkinson's disease (PD). Methods: In this prospective, multicenter, international, real-life cohort observation study of 173 PD patients undergoing STN-DBS (n = 101), IJLI (n = 33), or APO (n = 39) were followed-up using PDQuestionnaire-8, NMSScale (NMSS), Unified PD Rating Scale (UPDRS)-III, UPDRS-IV, and levodopa equivalent daily dose (LEDD) before and 6 months after intervention. Outcome changes were analyzed with Wilcoxon signed-rank or paired t test when parametric tests were applicable. Multiple... (More)
Objective: Real-life observational report of clinical efficacy of bilateral subthalamic stimulation (STN-DBS), apomorphine (APO), and intrajejunal levodopa infusion (IJLI) on quality of life, motor, and nonmotor symptoms (NMS) in Parkinson's disease (PD). Methods: In this prospective, multicenter, international, real-life cohort observation study of 173 PD patients undergoing STN-DBS (n = 101), IJLI (n = 33), or APO (n = 39) were followed-up using PDQuestionnaire-8, NMSScale (NMSS), Unified PD Rating Scale (UPDRS)-III, UPDRS-IV, and levodopa equivalent daily dose (LEDD) before and 6 months after intervention. Outcome changes were analyzed with Wilcoxon signed-rank or paired t test when parametric tests were applicable. Multiple comparisons were corrected (multiple treatments/scales). Effect strengths were quantified with relative changes, effect size, and number needed to treat. Analyses were computed before and after propensity score matching, balancing demographic and clinical characteristics. Results: In all groups, PDQuestionnaire-8, UPDRS-IV, and NMSS total scores improved significantly at follow-up. Levodopa equivalent daily dose was significantly reduced after STN-DBS. Explorative NMSS domain analyses resulted in distinct profiles: STN-DBS improved urinary/sexual functions, mood/cognition, sleep/fatigue, and the miscellaneous domain. IJLI improved the 3 latter domains and gastrointestinal symptoms. APO improved mood/cognition, perceptual problems/hallucinations, attention/memory, and the miscellaneous domain. Overall, STN-DBS and IJLI seemed favorable for NMSS total score, and APO favorable for neuropsychological/neuropsychiatric NMS and PDQuestionnaire-8 outcome. Conclusions: This is the first comparison of quality of life, nonmotor. and motor outcomes in PD patients undergoing STN-DBS, IJLI, and APO in a real-life cohort. Distinct effect profiles were identified for each treatment option. Our results highlight the importance of holistic nonmotor and motor symptoms assessments to personalize treatment choices.
(Less)
- author
- Dafsari, Haidar S.
; Martinez-Martin, Pablo
; Rizos, Alexandra
; Trost, Maja
; dos Santos Ghilardi, Maria Gabriela
; Reddy, Prashanth
; Sauerbier, Anna
; Petry-Schmelzer, Jan Niklas
; Kramberger, Milica
; Borgemeester, Robbert W.K.
; Barbe, Michael T.
; Ashkan, Keyoumars
; Silverdale, Monty
; Evans, Julian
; Odin, Per
LU
; Fonoff, Erich Talamoni
; Fink, Gereon R.
; Henriksen, Tove
; Ebersbach, Georg
; Pirtošek, Zvezdan
; Visser-Vandewalle, Veerle
; Antonini, Angelo
; Timmermann, Lars
and Ray Chaudhuri, K.
(Less) - author collaboration
- organization
- publishing date
- 2019-02-04
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Apomorphine, Deep brain stimulation, Intrajejunal levodopa infusion, Nonmotor symptoms, Quality of life
- in
- Movement Disorders
- publisher
- John Wiley & Sons Inc.
- external identifiers
-
- scopus:85061050019
- pmid:30719763
- ISSN
- 0885-3185
- DOI
- 10.1002/mds.27626
- language
- English
- LU publication?
- yes
- id
- 03b24aa0-59ad-4f4e-9ca6-f384f8cdb735
- date added to LUP
- 2019-02-14 09:45:22
- date last changed
- 2024-06-12 07:37:02
@article{03b24aa0-59ad-4f4e-9ca6-f384f8cdb735,
abstract = {{<p>Objective: Real-life observational report of clinical efficacy of bilateral subthalamic stimulation (STN-DBS), apomorphine (APO), and intrajejunal levodopa infusion (IJLI) on quality of life, motor, and nonmotor symptoms (NMS) in Parkinson's disease (PD). Methods: In this prospective, multicenter, international, real-life cohort observation study of 173 PD patients undergoing STN-DBS (n = 101), IJLI (n = 33), or APO (n = 39) were followed-up using PDQuestionnaire-8, NMSScale (NMSS), Unified PD Rating Scale (UPDRS)-III, UPDRS-IV, and levodopa equivalent daily dose (LEDD) before and 6 months after intervention. Outcome changes were analyzed with Wilcoxon signed-rank or paired t test when parametric tests were applicable. Multiple comparisons were corrected (multiple treatments/scales). Effect strengths were quantified with relative changes, effect size, and number needed to treat. Analyses were computed before and after propensity score matching, balancing demographic and clinical characteristics. Results: In all groups, PDQuestionnaire-8, UPDRS-IV, and NMSS total scores improved significantly at follow-up. Levodopa equivalent daily dose was significantly reduced after STN-DBS. Explorative NMSS domain analyses resulted in distinct profiles: STN-DBS improved urinary/sexual functions, mood/cognition, sleep/fatigue, and the miscellaneous domain. IJLI improved the 3 latter domains and gastrointestinal symptoms. APO improved mood/cognition, perceptual problems/hallucinations, attention/memory, and the miscellaneous domain. Overall, STN-DBS and IJLI seemed favorable for NMSS total score, and APO favorable for neuropsychological/neuropsychiatric NMS and PDQuestionnaire-8 outcome. Conclusions: This is the first comparison of quality of life, nonmotor. and motor outcomes in PD patients undergoing STN-DBS, IJLI, and APO in a real-life cohort. Distinct effect profiles were identified for each treatment option. Our results highlight the importance of holistic nonmotor and motor symptoms assessments to personalize treatment choices.</p>}},
author = {{Dafsari, Haidar S. and Martinez-Martin, Pablo and Rizos, Alexandra and Trost, Maja and dos Santos Ghilardi, Maria Gabriela and Reddy, Prashanth and Sauerbier, Anna and Petry-Schmelzer, Jan Niklas and Kramberger, Milica and Borgemeester, Robbert W.K. and Barbe, Michael T. and Ashkan, Keyoumars and Silverdale, Monty and Evans, Julian and Odin, Per and Fonoff, Erich Talamoni and Fink, Gereon R. and Henriksen, Tove and Ebersbach, Georg and Pirtošek, Zvezdan and Visser-Vandewalle, Veerle and Antonini, Angelo and Timmermann, Lars and Ray Chaudhuri, K.}},
issn = {{0885-3185}},
keywords = {{Apomorphine; Deep brain stimulation; Intrajejunal levodopa infusion; Nonmotor symptoms; Quality of life}},
language = {{eng}},
month = {{02}},
publisher = {{John Wiley & Sons Inc.}},
series = {{Movement Disorders}},
title = {{EuroInf 2 : Subthalamic stimulation, apomorphine, and levodopa infusion in Parkinson's disease}},
url = {{http://dx.doi.org/10.1002/mds.27626}},
doi = {{10.1002/mds.27626}},
year = {{2019}},
}